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We examined the relationship between use of progestagen-only before menopause (except for mini-pills) 
after the age of 40 and  invasive breast cancer risk in 73 664 women from the French E3N cohort study 
(mean age at start of follow-up, 51.8 years; mean duration of follow-up, 9.1 years). A total of 2 390 cases 
of invasive breast cancer were diagnosed during follow-up. Risk estimates were calculated using the Cox 
proportional hazard model. Overall, ever use of progestagen before menopause was not significantly 
associated with risk (relative risk (RR): 1.01, 95% confidence interval: 0.93–1.11). However, we observed 
a significant increase in risk associated with the duration of use (P-value for trend: 0.012), current use of 
progestagens for longer than 4.5 years being significantly associated with risk (RR: 1.44, 95% confidence 
interval: 1.03–2.00). Prolonged use of progestagens after the age of 40 may be associated with an 
increased risk of breast cancer and the subject needs to be investigated further. 
 
Keywords: breast cancer; progestagen; menopause 
 
 
Breast cancer is the most frequent malignancy among women in Western Europe, North America 
(Ferlay et al, 2001) and even in Japan (Minami et al, 2004). The hormonal dependence of breast cancer 
has been clearly demonstrated (Dunn et al, 2005) and risk factors include early age at menarche, 
nulliparity, late age at first birth, late age at menopause (Rosner et al, 1994) and the use of oral 
contraceptives (OCs) (Collaborative Group on Hormonal Factors in Breast Cancer, 1996) and hormone 
replacement therapy (HRT) (Greiser et al, 2005). 
Randomised trials and observational studies have strongly suggested that some synthetic 
progestagens, when added to an oestrogen in HRT, increase breast cancer risk more than the use of 
oestrogen alone (Chlebowski et al, 2003; Fournier et al, 2005; Stefanick et al, 2006). However, data on 
the impact of the premenopausal use of progestagens on breast cancer risk are limited. 
As progestagens alone (i.e. not associated with oestrogen) have long been prescribed in France to 
premenopausal women for menstrual disorders, oral contraception, benign uterine and ovarian diseases 
and certain benign breast diseases (Lowy and Weisz, 2005), we have investigated breast cancer risk in 
relation to the use of progestagens before menopause in women after the age of 40 from the E3N cohort. 
 
Materials and methods 
E3N is a French prospective cohort set up in 1990 to investigate cancer risk factors in women. A total of 
98 995 women, aged 40–64 years, belonging to the MGEN, a French health insurance scheme primarily 
covering teachers, and residing in France agreed to be volunteer by filling in the first questionnaire and a 
consent form. Since June 1990, participants have been asked at approximately 2-year intervals to complete 
self-administered questionnaires requesting information on various exposures and medical diagnoses. 
Information on lifetime use of hormonal treatments, including progestagens, was first recorded in the 
January 1992  questionnaire. To facilitate accurate recall, a booklet presenting an extensive list and colour 
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photographs of the hormonal treatments marketed in France was mailed to all study participants. Brand  
name, age at first use and duration of use were recorded for up to 24 periods of treatment. Information on 
hormonal treatment use was updated in each of the subsequent questionnaires. Information on the dose 
and the number of treatment days in the cycle was not requested. 
For the present study, the progestagens on which we focused were oral progestagens prescribed 
alone before menopause and after the age of 40 years. In France, progestagens are mainly prescribed for 
gynaecological disorders such as breast pain, uterine or ovarian pathologies and irregular menstruations, 
for perimenopausal disorders and for contraception. ‘Mini-pills’, because they were only occasionally 
used in our study population, were classified as OCs and were excluded from the present analysis. 
Cases were identified from self-reports of participants: all questionnaires asked them whether any 
cancer had been diagnosed, requesting the address of their physicians and permission to contact them to 
obtain the pathology reports. 
For the present study, follow-up started at the date of return of the second questionnaire (sent out 
in January 1992). It continued until the return of the follow-up questionnaire sent out in June 1993, 
January 1995, April 1997, June 2000 or July 2002, whichever was answered last. Person-years accrued 
until that date, or until diagnosis of cancer or death, whichever occurred first. 
Information on date of menopause, type of menopause, date of last menstruation, date of start of 
menopausal symptoms and date of hysterectomy were updated on receipt of each new questionnaire. 
Women for whom age at menopause could not be determined (e.g. women who reported a hysterectomy 
but gave no information on oophorectomy or menopausal symptoms, or women who indicated they were 
postmenopausal without any other information) were considered as menopausal at age 47 if menopause 
was artificial, and at age 51 otherwise, ages that corresponded in our cohort to the median age at 
menopause when artificial and natural, respectively. 
Women who had a prevalent cancer other than basal-cell carcinoma before inclusion (n = 11 200) 
were excluded, as well as women who had never menstruated (n = 25), those who never reached the 
second questionnaire (n = 1 066) and those who did not report either their date at the start of progestagen 
treatment or duration (n = 5 998). To focus the study on intake of progestagen during the perimenopause 
period, the analysis was restricted to women who had never used a progestagen before the age of 40 and 
who reached menopause after the age of 40. This left us with 73 664 women for the analysis, accruing 668 
033 person-years, with an average age at start of follow-up of 51.78 years (standard deviation (s.d.): 6.8) 
and a mean follow-up time of 9.07 years (s.d.: 2.4). 
Relative risks (RR) for breast cancer were estimated using Cox proportional hazards models. Age 
was used as the timescale. Known risk factors for breast cancer were included in the model, as well as 
confounding variables if they improved model fit by the P<0.3 criterion; these are indicated in the 
footnotes of the tables. Imputation to the mode was used for adjustment factors with 5% or less of missing 
values. Progestagen use was included in the model as a time-dependent variable. The referent group in 
each model consisted of women who indicated that they had never used any progestagen alone before 
menopause. 
Relative risks are given with 95% confidence intervals. The P-values for assessing possible 
heterogeneity in effect estimates were computed from likelihood ratio tests. The P-values for assessing 
possible trends were computed from likelihood ratio tests on continuous variables. All analyses were 
performed using SASs system, version 9.1. 
 
Results 
The main characteristics of the 73 664 women included in the analysis according to use of 
progestagen treatment alone are shown in Table 1. At the end of follow-up, ever users had later 
menopause and more frequently had a personal history of benign disease of the breast, uterus or ovary 
than never users. Ever use of OCs (oestrogen–progestagen and mini-pills) or of HRT, and mammographic 
follow-up were more frequent in ever users of progestagens, and young generations were more likely to 
have used progestagens than older women. 
Table 1 Selected characteristics (at the end of follow-up) of participants according to ever use of progestagens 
(n = 73 664) E3N cohort study (1990–2002) 
 Non-users 
n = 45 294 
Users 
n = 28 370 
 n (%) n (%) 
Year of birth 
1925 – 1937  
1938 – 1944  
1945 – 1951  
 
18 402 (40.62) 
11 024 (24.33) 
15 868 (35.05) 
 
5 030 (17.72) 
9 109 (32.10) 
14 231 (50.18) 
History of BC (first degree relatives) 
None  
1  
2 and +  
 
40 191 (88.73) 
4 640 (10.24) 
463 (1.03) 
 
25 027 (88.21) 
3 074 (10.83) 
269 (0.96) 
History of BC (second degree relatives) 
No  
Yes  
 
38 717 (85.47) 
6 577 (14.53) 
 
23 755 (83.73) 
4 615 (16.27) 
History of BUOD
a
 
No  
Yes  
 
27 199 (60.04) 
18 095 (39.96) 
 
14 096 (49.68) 
14 274 (50.32) 
History of BBD
a
 
No  
Yes  
 
35 122 (77.54) 
10 172 (22.46) 
 
18 418 (64.92) 
9 952 (35.08) 
Body mass index (premenopausal, kg m
-2
) 
<22  
22 –25  
25 –30   
>30  
 
279 (0.61) 
43 451 (95.93) 
1 214 (2.68) 
 350 (0.78) 
 
148 (0.52) 
27 257 (96.07) 
772 (2.72) 
193 (0.69) 
Age at menarche (years) 
<13  
13 –15  
>15  
 
20 798 (45.91) 
22 653 (50.01) 
1 843 (4.08) 
 
13 369 (47.12) 
14 134 (49.82) 
867 (3.06) 
Parity 
Nulliparous  
Age at first FTP>30 num=1
b
   
Age at first FTP>30 num>1  
Age at first FTP<= 30  
 
5 450 (12.03) 
1 836 (4.05) 
1 981 (4.37) 
36 027 (79.55) 
 
3 028 (10.67) 
1 101 (3.88) 
1 129 (3.97) 
23 112 (81.48) 
OC use 
Never  
Ever  
 
31 606 (69.77) 
13 688 (30.23) 
 
14 927 (52.61) 
13 443 (47.39) 
Age at menopause
c
 (years) 
<48  
48 –52  
>52   
 
9 871 (25.23) 
19 990 (51.09) 
9 266 (23.68) 
 
4 429 (18.24) 
12 995 (53.53) 
6 853 (28.23) 
HRT use
c
 
Never  
Ever  
 
14 541 (37.16) 
24 586 (62.84) 
 
2 679 (11.04) 
21 598 (88.96) 
Mammographic history 
Never  
Ever  
 
9 660 (21.32) 
35 634 (78.68) 
 
2 775 (9.78) 
25 595 (90.22) 
a
BUOD = benign uterine or ovarian disease; BBD = benign breast disease. 
b
FTP = Full-term pregnancy; num = 
number of FTP. 
c
Among postmenopausal women. 
 
During follow-up, 2390 cases of new primary invasive breast cancer were identified among the 73 
664 women in the cohort. Pathology reports were obtained for 95.27% of cases. In all, 443 802 person-
years were associated with never-use and 224 231 personyears with ever-use, in which 1 510 and 880 
cases of invasive breast cancer were recorded, respectively. Overall, there was no significant association 
between ever-use of progestagen and breast cancer risk (RR: 1.01; P = 0.77). The relationship between 
ever-use of progestagens and breast cancer risk did not vary significantly by previous use of OC (P for 
interaction: 0.57), by personal history of benign breast disease (P for interaction: 0.86), by personal 
history of benign uterine or ovarian disease (P for interaction: 0.19) or mammographic history (P for 
interaction: 0.23). 
However, we found a significant increase in breast cancer risk with increasing duration of 
use (P for trend=0.012, Table 2). We investigated associations according to time since first use 
and time since last use but did not find any significant association or trend (Table 2). 
 
Table 2 Relative risk associated with the use of progestagens according to duration, time since first use and 
time since last use, compared with never use (n¼73 664). E3N cohort study (1990–2002) 
 PY
a
 Cases RRa,b 95% CIa 
Never use 
Ever use 
443 802 
224 231 
1 510 
880 
1.00 
1.01 
 
0.93 – 1.11 
Duration (years)
c
 
   <1  
   1–2.5    
   2.5– 4.5  
   >4.5   
   Trend (per year of use)  
 
83 449 
63 932 
43 712 
33 138 
 
 
272 
272 
174 
162 
 
0.90 
1.00 
1.10 
1.13 
1.03 
 
0.79 – 1.03 
0.85 – 1.17 
0.96 – 1.26 
0.96 – 1.33 
1.01 – 1.06 
Interval since first use (years)
c
 
   <4    
   4–7.5    
   7.5– 11.5   
   >11.5   
   Trend (per year since first use)  
 
70 591 
61 804 
48 026 
43 810 
 
235 
235 
209 
201 
 
1.03 
1.04 
1.04 
0.95 
0.99 
 
0.89 – 1.18 
0.90 – 1.20 
0.90 – 1.21 
0.81 – 1.11 
0.98 – 1.01 
Interval since last use (years)
c
 
Current use   
<3   
3–6   
6–9.5    
>9.5   
Trend (per year since last use)  
 
68 697 
68 108 
40 004 
25 511 
21 863 
 
235 
265 
175 
111 
94 
 
1.14 
0.96 
1.07 
0.97 
0.92 
0.99 
 
0.97 – 1.33 
0.84 – 1.10 
0.91 – 1.26 
0.80 – 1.19 
0.75 – 1.14 
0.98 – 1.01 
a
PY = person-year; RR = relative risk; CI = confidence interval. 
b
Adjusted for BMI before and after menopause 
(<22/22-25/25-30/>=30), menopausal status (premenopausal/artificial menopause/natural menopause), age at 
menopause (<48/48 – 52/>52), parity and age at first FTP (nulliparous/first FTP at age < 30/first FTP at age ≥30, 
num=1/first FTP at age ≥-30, num>1), age at menarche (<13/13 – 15/>15), familial history of breast cancer in sisters, 
mother, children (no/1/more than 1), familial history of breast cancer in other relatives (yes/no), personal history of 
benign breast disease (yes/no), personal history of benign uterin or ovarian disease (yes/no), use of oral contraceptive 
(never/current or < 5 years after stop/ >5 years after stop), use of HRT (No/oestrogen 
alone/oestrogen+progestin/oestrogen+progesterone/others) and previous mammography (yes/no) Time-dependent 
variables. 
c
Categories correspond to quartiles. 
 
Results on duration of use were further stratified according to recency of use (Table 3). We found 
that, among current users, use longer than 4.5 years was significantly associated with breast cancer risk 
(RR=1.44; P=0.034), but not use shorter than 4.5 years. After discontinuation, and whatever the duration, 
the risks were close to unity. There was no significant trend towards decreasing risk with increasing time 
since last use (Table 3). 
Table 3 Relative risk associated with the use of progestagens according to duration and recency of use, 
compared with never use (n=73 664). E3N cohort study (1990–2002) 
 Duration of use (years) 
 <4.5  ≥4.5 
Recency of use [PY; cases] RR
a
 95% CI  [PY; cases] RR
a
 95% CI 
Current use   
Past use   
Trend (per year since last use)  
[58 751;193] 
[132 341;525] 
1.09 
0.97 
0.99 
0.92 – 1.29 
0.87 – 1.07 
0.98 – 1.01 
 [9 946;42] 
[23 193;120] 
1.44 
1.06 
0.97 
1.03 – 2.00 
0.88 – 1.27 
0.95 – 1.01 
a
Adjusted for the same covariates as in Table 2. 
 
 
Because many women (48.4% of progestagens users) changed or temporarily interrupted their 
treatment, we verified that this did not modify risk patterns. Analyses conducted separately on women 
who had never interrupted nor changed their treatment and on women who declared at least one temporary 
interruption or a change yielded comparable results (data not shown). 
Finally, we investigated associations according to whether treatment was possibly 
antigonadotrophic (cyproterone acetate, medroxyprogesterone acetate, nomegestrol acetate, 
chlormadinone acetate, ethynodiol, norethisterone acetate, lynestrenol and promegestone) or not 
(progesterone, retroprogesterone, medrogestone and demegestone). Overall, patterns of risk did not show 
marked differences (P for homogeneity: 0.35). 
 
Discussion 
We did not find a significant association between breast cancer risk and ever-use of a progestagen 
before menopause. However, we found a significant trend towards increasing risk with increasing duration 
of use, and current use of treatment for longer than 4.5 years was positively and significantly associated 
with risk. 
A previous study showed a significant decrease in breast cancer risk associated with the use of an 
oral nonsteroid progestin alone (Plu-Bureau et al, 1994), although based on only 15 cases in a cohort of 
1150 women with benign breast disease, meaning that any conclusion on the impact of progestins in the 
general population was difficult to draw. 
Some studies found an increase in risk associated with the use of a progestagen-only HRT 
(Magnusson et al, 1999; Newcomb et al, 2002; Beral, 2003; Dinger et al, 2006), but these studies 
involved small numbers of cases. Also, the unusual use of a progestagen-only HRT may reflect the 
particular profile of the women receiving such treatment, or even misclassification (underreporting 
oestrogen). 
Studies on HRT have shown that a combination of oestrogen plus progestin increases breast 
cancer risk more than oestrogen alone (Chlebowski et al, 2003; Fournier et al, 2005; Stefanick et al, 
2006), but these involve administration to postmenopausal women. 
In vivo studies have supported a role for progesterone in the induction of cyclic proliferation in the 
breast (reviewed in Graham and Clarke, 1997), although they were not consistent with clinical trials that 
found that percutaneous progesterone acts as an inhibitor of oestrogen-induced proliferation (Chang et al, 
1995; Foidart et al, 1998). In vitro studies have also produced inconsistent results with progesterone acting 
as a proliferative (Edery et al, 1984; McGrath et al, 1985) or an antiproliferative (Clark and Peck, 1979; 
McManus and Welsch, 1984; Malet et al, 2000) agent in normal breast cells. 
Overall, these results tend to suggest a deleterious effect of oral progestagens on breast cancer 
risk. However, different progestagens may affect risk differently, and the estrogenic environment may also 
modify their effect (Pasqualini et al, 1998), so it would be premature to conclude an overall class effect of 
progestagens, particularly as studies like ours specifically addressing the relationship between oral 
progestagens given alone before menopause (except for mini pills) and risk are rare. 
Our results are consistent with a promoting effect of progestagens on tumour cells, by showing an 
increase in risk with increasing duration, and suggesting a return to baseline risk after discontinuation. A 
similar effect has been demonstrated for depot medroxyprogesterone acetate (Skegg et al, 1995) and for 
mini-pills (Collaborative Group on Hormonal Factors in Breast Cancer, 1996; Kumle et al, 2002); those 
authors suggested that recent use was positively and significantly associated with breast cancer risk, and 
that the risk was close to unity after discontinuation. Our results are in agreement with others 
(Collaborative Group on Hormonal Factors in Breast Cancer, 1996, 1997; Lee et al, 2005) suggesting that 
the increase in risk might be limited to current use of hormonal treatments. 
Our study had some limitations. We did not record any details on the treatment (number of days 
per month, dose) and hence could not analyse the risk associated with intermittent or continuous use or 
with dose. Although the reasons for prescribing progestagens were not recorded, a potential ‘prescription’ 
bias is unlikely, because we adjusted for the variables ‘personal history of benign breast disease’ and 
‘personal history of benign uterine or ovarian disease’, and because the effect of progestagens on breast 
cancer risk did not vary significantly by personal history of benign breast disease or by personal history of 
benign uterine or ovarian disease. The effect of progestagens on breast cancer risk did not differ 
significantly according to OC use. Misclassification of progestagen exposure, which was based on self-
reported information, may have affected our results, but given the prospective design, this should be non-
differential between cases and noncases, and would tend to reduce the magnitude of the relationship with 
risk, and dampen differences in the effects of different progestagens. 
Finally, there is limited scope for ‘surveillance bias’ owing to progestagen users being more likely 
to have repeated mammograms, because this was adjusted for, and because the effect of progestagens on 
risk did not differ significantly according to mammographic history. 
In conclusion, our study suggests that the use, before menopause, of oral progestagens (without 
oestrogens) by women over 40 may increase breast cancer risk. Further follow-up study will enable more 
exhaustive analysis using specific categories of progestagens. 
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